Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Programmed Cell Death 1 Ligand 1(PDL1, PD-L1)”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Ended earlyNCT04515979
What this trial is testing

Vactosertib in Combination with Pembrolizumab for PD-L1 Positive Non-small Cell Lung Cancer (NSCLC) Subjects

Who this might be right for
Carcinoma, Non-Small-Cell Lung
MedPacto, Inc. 11
Early research (Phase 1)Looking for participantsNCT04740424
What this trial is testing

FS222 First in Human Study in Patients With Advanced Malignancies

Who this might be right for
Advanced CancerMetastatic Cancer
invoX Pharma Limited 260
Large-scale testing (Phase 3)Ended earlyNCT04738487
What this trial is testing

Coformulation of Pembrolizumab/Vibostolimab (MK-7684A) Versus Pembrolizumab (MK-3475) Monotherapy for Programmed Cell Death 1 Ligand 1 (PD-L1) Positive Metastatic Non-Small Cell Lung Cancer (MK-7684A-003, KEYVIBE-003)

Who this might be right for
Lung NeoplasmsNon-Small-Cell Lung Carcinoma
Merck Sharp & Dohme LLC 1,264
Early research (Phase 1)Study completedNCT02734160
What this trial is testing

Galunisertib (LY2157299) and Durvalumab (MEDI4736) in Participants With Metastatic Pancreatic Cancer

Who this might be right for
Metastatic Pancreatic Cancer
Eli Lilly and Company 37
Not applicableStudy completedNCT04507191
What this trial is testing

PDL1 in Ovarian High Grade Serous Carcinoma

Who this might be right for
Ovarian Cancer
Port Said University hospital 54
Early research (Phase 1)Study completedNCT02721589
What this trial is testing

Evaluate the Safety and Tolerability of Using the SHR-1210 by Advanced Solid Tumor Subjects

Who this might be right for
Advanced Solid Tumors
Jiangsu HengRui Medicine Co., Ltd. 126
Testing effectiveness (Phase 2)Looking for participantsNCT06953089
What this trial is testing

DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors

Who this might be right for
Solid Tumors
DualityBio Inc. 450
Early research (Phase 1)Looking for participantsNCT06504368
What this trial is testing

Safety, Tolerability, and Pharmacokinetics of DCR-PDL1 in Adults With Solid Tumors

Who this might be right for
Solid Tumors, Adult
Dicerna Pharmaceuticals, Inc., a Novo Nordisk company 32
Large-scale testing (Phase 3)Study completedNCT02551159
What this trial is testing

Phase III Open Label Study of MEDI 4736 With/Without Tremelimumab Versus Standard of Care (SOC) in Recurrent/Metastatic Head and Neck Cancer

Who this might be right for
Squamous Cell Carcinoma of the Head and Neck
AstraZeneca 823
Testing effectiveness (Phase 2)Ended earlyNCT03598608
What this trial is testing

Study to Evaluate the Safety and Efficacy of a Combination of Favezelimab (MK-4280) and Pembrolizumab (MK-3475) in Participants With Hematologic Malignancies (MK-4280-003)

Who this might be right for
Hodgkin DiseaseLymphoma, Non-HodgkinLymphoma, B-Cell
Merck Sharp & Dohme LLC 137
Large-scale testing (Phase 3)Study completedNCT03834506
What this trial is testing

Study of Pembrolizumab (MK-3475) Plus Docetaxel Versus Placebo Plus Docetaxel in Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-921/KEYNOTE-921)

Who this might be right for
Prostatic Neoplasms
Merck Sharp & Dohme LLC 1,030
Testing effectiveness (Phase 2)Study completedNCT03202758
What this trial is testing

Evaluation of the Safety and the Tolerability of Durvalumab Plus Tremelimumab Combined With FOLFOX in mCRC

Who this might be right for
Colorectal Cancer Metastatic
Centre Georges Francois Leclerc 57
Testing effectiveness (Phase 2)Active Not RecruitingNCT06773910
What this trial is testing

BMS-986489 (Atigotatug + Nivolumab) vs Durvalumab in Limited-stage Small-cell Lung Cancer (TIGOS-LS)

Who this might be right for
Limited Stage Small Cell Lung Cancer
SCRI Development Innovations, LLC 250
Very early researchLooking for participantsNCT07274813
What this trial is testing

A Phase I Study to Evaluate the Safety, Tolerability, and PK of HLX37 in Advanced/Metastatic Solid Tumors

Who this might be right for
Advanced/Metastatic Solid TumorsNSCLC
Shanghai Henlius Biotech 254
Testing effectiveness (Phase 2)Active Not RecruitingNCT03620578
What this trial is testing

DA-EPOCH-R Induction Followed by Nivolumab Consolidation in Newly Diagnosed MYC, BCL2 and/or BCL6 Rearranged HGBL

Who this might be right for
Non Hodgkin LymphomaLymphoma, B-CellHigh-grade B-cell Lymphoma+2 more
Stichting Hemato-Oncologie voor Volwassenen Nederland 97
Testing effectiveness (Phase 2)WithdrawnNCT03169738
What this trial is testing

QUILT-3.044: NANT Non-small Cell Lung Cancer (NSCLC) Vaccine: Combination Immunotherapy in Subjects With NSCLC Who Have Progressed After Treatment With PD-1/PD-L1 Inhibitors

Who this might be right for
Non-small Cell Lung Cancer
ImmunityBio, Inc.
Testing effectiveness (Phase 2)UnknownNCT04799548
What this trial is testing

A Phase II Study of TACE Plus PD-1 Antibody in the Locally Advanced Stomach Adenocarcinoma

Who this might be right for
Advanced Gastric Cancer
Shanghai Zhongshan Hospital 71
Testing effectiveness (Phase 2)Ended earlyNCT03770455
What this trial is testing

Avelumab Plus 2nd-generation ADT in African American Subjects With mCRPC

Who this might be right for
Metastatic Castration-resistant Prostate Cancer
Jodi Layton, MD 8
Testing effectiveness (Phase 2)Looking for participantsNCT06016920
What this trial is testing

Safety and Efficacy of VB10.16 and Pembrolizumab in Patients With Head-Neck Squamous Cell Carcinoma

Who this might be right for
HPV Positive Oropharyngeal Squamous Cell CarcinomaHNSCC
Nykode Therapeutics ASA 110
Testing effectiveness (Phase 2)Active Not RecruitingNCT04215146
What this trial is testing

Assess Overall Response Rate by Inducing an Inflammatory Phenotype in Metastatic BReast cAnCEr With the Oncolytic Reovirus PeLareorEp in CombinaTion With Anti-PD-L1 Avelumab and Paclitaxel - BRACELET-1 Study

Who this might be right for
Breast Cancer Metastatic
Oncolytics Biotech 48
Next Page